212 related articles for article (PubMed ID: 34556815)
1. Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes.
Lebedev T; Vagapova E; Spirin P; Rubtsov P; Astashkova O; Mikheeva A; Sorokin M; Vladimirova U; Suntsova M; Konovalov D; Roumiantsev A; Stocking C; Buzdin A; Prassolov V
Oncogene; 2021 Nov; 40(44):6258-6272. PubMed ID: 34556815
[TBL] [Abstract][Full Text] [Related]
2. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
4.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
5. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
Li H; Wang Y; Chen Z; Lu J; Pan J; Yu Y; Zhao Y; Zhang H; Hu T; Liu Q; Yang J
Oncotarget; 2017 Jan; 8(4):5874-5884. PubMed ID: 27564113
[TBL] [Abstract][Full Text] [Related]
6. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
7. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
8. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
10. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
11. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
[TBL] [Abstract][Full Text] [Related]
12. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
13. Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells.
Eggert A; Ikegaki N; Liu X; Chou TT; Lee VM; Trojanowski JQ; Brodeur GM
Oncogene; 2000 Apr; 19(16):2043-51. PubMed ID: 10803465
[TBL] [Abstract][Full Text] [Related]
14. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways.
Cheng J; Fan YH; Xu X; Zhang H; Dou J; Tang Y; Zhong X; Rojas Y; Yu Y; Zhao Y; Vasudevan SA; Zhang H; Nuchtern JG; Kim ES; Chen X; Lu F; Yang J
Cell Death Dis; 2014 Feb; 5(2):e1079. PubMed ID: 24556694
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.
Czarnecka M; Trinh E; Lu C; Kuan-Celarier A; Galli S; Hong SH; Tilan JU; Talisman N; Izycka-Swieszewska E; Tsuei J; Yang C; Martin S; Horton M; Christian D; Everhart L; Maheswaran I; Kitlinska J
Oncogene; 2015 Jun; 34(24):3131-43. PubMed ID: 25132261
[TBL] [Abstract][Full Text] [Related]
16.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
17. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.
Salm F; Cwiek P; Ghosal A; Lucia Buccarello A; Largey F; Wotzkow C; Höland K; Styp-Rekowska B; Djonov V; Zlobec I; Bodmer N; Gross N; Westermann F; Schäfer SC; Arcaro A
Oncogene; 2013 Aug; 32(34):3944-53. PubMed ID: 23027129
[TBL] [Abstract][Full Text] [Related]
18. Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.
Wang Y; Chen K; Cai Y; Cai Y; Yuan X; Wang L; Wu Z; Wu Y
J Exp Clin Cancer Res; 2017 Aug; 36(1):111. PubMed ID: 28814318
[TBL] [Abstract][Full Text] [Related]
19. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
20. Subtype of Neuroblastoma Cells with High KIT Expression Are Dependent on KIT and Its Knockdown Induces Compensatory Activation of Pro-Survival Signaling.
Lebedev T; Buzdin A; Khabusheva E; Spirin P; Suntsova M; Sorokin M; Popenko V; Rubtsov P; Prassolov V
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]